350 rub
Journal Technologies of Living Systems №2 for 2013 г.
Article in number:
Vascular endothelial growth factor as a key angiogenesis regulator and clinically valuable marker in different malignant neoplasms
Keywords: vascular endothelial growth factor (VEGF) VEGF receptors angiogenesis human tumors prognosis
Authors:
E.S. Gershtein, D.N. Kushlinsky, V.G. Degtiyar
Abstract:
Results of authors - investigations performed on more than 400 breast, ovarian, endometrial, renal, esophageal cancer patients, as well as the most representative literature data indicating that the key positive neoangiogenesis regulator - vascular endothelial growth factor (VEGF) ? is a clinically significant prognostic factor in various oncologic diseases are demonstrated. Namely, high tumor VEGF level is an unfavorable marker for both early and advanced breast cancer. Its role as a serological factor for diagnostics and monitoring needs further investigation. VEGF is also a molecular target for several modern drugs with different mechanisms of action. These anti-VEGF drugs are most successfully applied in the treatment of colorectal cancer (Avastin) and renal cancer (inhibitors of VEGF receptor tyrosine kinase).
Pages: 18-33
References
  1. ADDIN EN.REFLIST 1.    Герштейн Е.С., Грицаенко Е.В., Щербаков М.Е. и др. Фактор роста эндотелия сосудов и компоненты системы активации плазминогена при раке и гиперплазии эндометрия Вопросы онкологии. 2003. № 49 (6). С. 725 - 729.
  2. Герштейн Е.С., Кушлинский Д.Н., Левкина Н.В. и др. Взаимосвязь экспрессии компонентов VEGF-сиг­нального пути и матриксных металлопротеиназ в опухолях больных с новообразованиями яичников // Бюллетень экспериментальной биологии и медицины. 2011. № 151 (4). С. 431 - 435.
  3. Герштейн Е.С., Левкина Н.В., Дигаева М.А. и др.  Матриксные металлопротеиназы 2, 7, 9 и тканевой ингибитор матриксных металлопротеиназ 1 типа в опухолях и сыворотке крови больных новообразованиями яичников // Бюллетень экспериментальной биологии и медицины. 2010. Т. 149 (5). С. 562 - 565.
  4. Герштейн Е.С., Щербаков А.М., Алиева С.К. и др. Фактор роста эндотелия сосудов в опухолях и сыворотке крови больных раком молочной железы // Бюллетень экспериментальной биологии и медицины. 2003. № 135 (1). С. 85 - 88.
  5. Герштейн Е.С., Щербаков А.М., Алиева С.К. и др. Фактор роста эндотелия сосудов в опухолях и сыворотке крови больных раком молочной железы: связь с клинико-морфологическими факторами // Вестник Российского онкологического научного центра им. Н.Н. Блохина РАМН. 2005. № 1-2. С. 26 - 30.
  6. Герштейн Е.С., Щербаков А.М., Гончаров Д.Ю. и др. Фактор роста эндотелия сосудов при раке пищевода // Вопросы биологической медицинской и фармацевтической химии. 2004. № 1. С. 26 - 29.
  7. Ким Е.А., Герштейн Е.С., Высоцкая И.В., Кушлинский Н.Е. Экспрессия VEGF и VEGFR2 в опухолях в процессе неоадъювантного лечения больных раком молочной железы // Бюллетень экспериментальной биологии и медицины. 2008. Т. 145. № 2. С. 206 - 209.
  8. Ким Е.А., Герштейн Е.С., Щербаков А.М. и др. Влияние неоадъювантной терапии на уровни VEGF и VEGFR-2 в опухолях и сыворотке крови больных раком молочной железы // Вопросы онкологии. 2008. Т. 54. № 3. С. 287 - 293.
  9. Кушлинский Д.Н., Герштейн Е.С., Ермилова В.Д. и др. Фактор роста эндотелия сосудов и его рецепторы 1-го и 2-го типа в сыворотке крови больных новообразованиями яичников // Вопросы биологической, медицинской и фармацевтической химии. 2012. № 10. С. 30 - 35.
  10. 10.  Кушлинский Н.Е., Герштейн Е.С. Роль фактора роста эндотелия сосудов при раке молочной железы // Бюллетень экспериментальной биологии и медицины. 2002. Т. 133. № 6. С. 604 - 612.
  11. Кушлинский Н.Е., Трапезникова М.Ф., Герштейн Е.С. и др. Фактор роста эндотелия сосудов и его рецептор 2 типа при раке почки // Вопросы биологической, медицинской и фармацевтической химии. 2008. № 5. С. 31 - 33.
  12. Кушлинский Н.Е., Трапезникова М.Ф., Глыбин П.А. и др. Фактор роста эндотелия сосудов и его рецептор 2-го типа в опухолях и сыворотке крови больных раком почки // Бюллетень экспериментальной биологии и медицины. 2008. Т. 145. № 6. С. 691 - 694.
  13. Щербаков А.М., Герштейн Е.С., Анурова О.А., Кушлинский Н.Е. Фактор роста эндотелия сосудов и его рецепторы первого и второго типа при раке молочной железы // Вопросы онкологии. 2005. Т.51. № 3. С. 317 - 321.
  14. Off-label uses of bevacizumab: renal cell carcinoma and other miscellaneous non-colorectal cancer indications // Technol. Eval. Cent. Asses. Program. Exec. Summ. 2006. V. 21. № 9. P. 1 - 4.
  15. Abir R., Ao A., Zhang X.Y. et al. Vascular endothelial growth factor A and its two receptors in human preantral follicles from fetuses, girls, and women // Fertil. Steril. 2010. V. 93. № 7. P. 2337 - 2347.
  16. Adams J., Carder P.J., Downey S. et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen // Cancer Res. 2000. V. 60. № 11. P. 2898 - 2905.
  17. Aesoy R., Sanchez B.C., Norum J.H. et al. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells // Mol. Cancer Res. 2008. V. 6. № 10. P.1630 - 1638.
  18. Anan K., Morisaki T., Katano M. et al. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer // Surgery. 1996. V. 119. № 3. P. 333 - 339.
  19. Anan K., Morisaki T., Katano M. et al. Assessment of c-erbB2 and vascular endothelial growth factor mRNA expression in fine-needle aspirates from early breast carcinomas: pre-operative determination of malignant potential // Eur. J. Surg. Oncol. 1998. V. 24. № 1. P. 28 - 33.
  20. Araujo V.R., Duarte A.B., Bruno J.B. et al. Importance of vascular endothelial growth factor (VEGF) in ovarian physiology of mammals // Zygote. 2011. P. 1 - 10.
  21. Artini P.G., Cristello F., Monti M. et al. Vascular endothelial growth factor and its soluble receptor in ovarian pathology // Gynecol. Endocrinol. 2005. V. 21. № 1. P. 50 - 56.
  22. Artini P.G., Ruggiero M., Monteleone P. et al. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors // Biomed. Pharmacother. 2008. V. 62. № 6. P. 373 - 377.
  23. Belotti D., Calcagno C., Garofalo A. et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion // Mol. Cancer Res. 2008. V. 6. № 4. P. 525 - 534.
  24. Blancher C., Moore J.W., Robertson N., Harris A.L. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway // Cancer Res. 2001. V. 61. № 19. P. 7349 - 7355.
  25. Brown L.F., Guidi A.J., Schnitt S.J. et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast // Clin. Cancer Res. 1999. V. 5. № 5. P. 1041 - 1056.
  26. Callagy G., Dimitriadis E., Harmey J. et al. Immunohistochemical measurement of tumor vascular endothelial growth factor in breast cancer. A more reliable predictor of tumor stage than microvessel density or serum vascular endothelial growth factor // Appl. Immunohistochem. Mol. Morphol. 2000. V. 8. № 2. P. 104 - 109.
  27. Chambers S.K., Clouser M.C., Baker A.F. et al. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer // Clin. Cancer Res. 2010. V. 16. № 21. P. 5320 - 5328.
  28. Chen H., Ye D., Xie X. et al. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma // Gynecol. Oncol. 2004. V. 94. № 3. P. 630 - 635.
  29. Chen M., Cai E., Huang J. et al. Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis // Cancer Epidemiol. Biomarkers Prev. 2012. V. 21. № 7. P. 1126 - 1134.
  30. Collinson F.J., Hall G.D., Perren T.J., Jayson G.C. Development of antiangiogenic agents for ovarian cancer // Expert Rev Anticancer Ther. 2008. V. 8. № 1. P. 21 - 32.
  31. Cook K.M., Figg W.D. Angiogenesis inhibitors: current strategies and future prospects // CA Cancer J. Clin. 2010. V. 60. № 4. P. 222 - 243.
  32. Cooper B.C., Ritchie J.M., Broghammer C.L. et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer // Clin. Cancer Res. 2002. V. 8. № 10. P. 3193 - 3197.
  33. Coradini D., Boracchi P., Daidone M.G. et al. Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer // Br. J. Cancer. 2001. V. 85. № 6. P. 795 - 797.
  34. Dirix L.Y., Vermeulen P.B., Pawinski A. et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients // Br. J. Cancer. 1997. V. 76. № 2. P. 238 - 243.
  35. Eppenberger U., Kueng W., Schlaeppi J.M. et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients // J. Clin. Oncol. 1998. V. 16. № 9. P. 3129 - 3136.
  36. Ferrara N., Heinsohn H., Walder C.E. et al. The regulation of blood vessel growth by vascular endothelial growth factor // Ann. N. Y. Acad. Sci. 1995. V. 752. P. 246 - 256.
  37. Fine B.A., Valente P.T., Feinstein G.I., Dey T. VEGF,
    flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma // Gynecol. Oncol. 2000. V. 76. № 1. P. 33 - 39.
  38. Foca C., Moses E.K., Quinn M.A., Rice G.E. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas // Gynecol. Oncol. 2000. V. 79. № 2. P. 244 - 250.
  39. Foekens J.A., Peters H.A., Grebenchtchikov N. et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer // Cancer Res. 2001. V. 61. № 14. P. 5407 - 5414.
  40. Fredstorp-Lidebring M., Bendahl P.O., Brunner N. et al. Urokinase plasminogen activator and its inhibitor,
    PAI-1, in association with progression-free survival in early stage endometrial cancer // Eur. J. Cancer. 2001. V. 37. № 18. P. 2339 - 2348.
  41. Fujisawa T., Watanabe J., Akaboshi M. et al. Immunohistochemical study on VEGF expression in endometrial carcinoma - comparison with p53 expression, angiogenesis, and tumor histologic grade // J. Cancer Res. Clin. Oncol. 2001. V. 127. № 11. P. 668 - 674.
  42. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer // Oncologist. 2000. V. 5. Suppl 1. P. 37 - 44.
  43. Gasparini G. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer // Crit. Rev. Oncol. Hematol. 2001. V. 37. № 2. P. 97 - 114.
  44. Gasparini G., Toi M., Miceli R. et al. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy // Cancer J. Sci. Am. 1999. V. 5. № 2. P. 101 - 111.
  45. Giatromanolaki A., Sivridis E., Brekken R. et al. The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications // Cancer. 2001. V. 92. № 10. P. 2569 - 2577.
  46. Gray R.T., O'Donnell M.E., McGuigan J.A., Spence G.M. Quantification of tumour and circulating vascular endothelial growth factor (VEGF) in patients with oesophagogastric cancer: a long-term follow-up study // Br. J. Biomed. Sci. 2012. V. 69. № 2. P. 71 - 75.
  47. Greb R.R., Maier I., Wallwiener D., Kiesel L. Vascular endothelial growth factor A (VEGF-A) mRNA expression levels decrease after menopause in normal breast tissue but not in breast cancer lesions // Br. J. Cancer. 1999. V. 81. № 2. P. 225 - 231.
  48. Guidi A.J., Schnitt S.J., Fischer L. et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast // Cancer. 1997. V. 80. № 10. P. 1945 - 1953.
  49. Gutman G., Barak V., Maslovitz S. et al. Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis // Fertil. Steril. 2008. V. 89. № 4. P. 922 - 926.
  50. Harshman L.C., Xie W., Bjarnason G.A. et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study // Lancet. Oncol. 2012. V. 13. № 9. P. 927 - 935.
  51. Hata K., Watanabe Y., Nakai H. et al. Expression of the vascular endothelial growth factor (VEGF) gene in epithelial ovarian cancer: an approach to anti-VEGF therapy // Anticancer Res. 2011. V. 31. № 2. P. 731 - 737.
  52. Hefler L.A., Zeillinger R., Grimm C. et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer // Gynecol. Oncol. 2006. V. 103. № 2. P. 512 - 517.
  53. Heng D.Y., Xie W., Regan M.M. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study // J. Clin. Oncol. 2009. V. 27. № 34. P. 5794 - 5799.
  54. Hyder S.M., Nawaz Z., Chiappetta C., Stancel G.M. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor // Cancer Res. 2000. V. 60. № 12. P. 3183 - 3190.
  55. Hyder S.M., Stancel G.M. Regulation of VEGF in the reproductive tract by sex-steroid hormones // Histol. Histopathol. 2000. V. 15. № 1. P. 325 - 334.
  56. Karihtala P., Maenpaa J., Turpeenniemi-Hujanen T., Puistola U. Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial // Anticancer Res. 2010. V. 30. № 3. P. 1001 - 1006.
  57. Koukourakis M.I., Limberis V., Tentes I. et al. Serum VEGF levels and tissue activation of VEGFR2/KDR receptors in patients with breast and gynecologic cancer // Cytokine. 2011. V. 53. № 3. P. 370 - 375.
  58. Kraft A., Weindel K., Ochs A. et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease // Cancer. 1999. V. 85. № 1. P. 178 - 187.
  59. Kranz A., Mattfeldt T., Waltenberger J. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer // Int. J. Cancer. 1999. V. 84. № 3. P. 293 - 298.
  60. Laughner E., Taghavi P., Chiles K. et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression // Mol. Cell. Biol. 2001. V. 21. № 12. P. 3995 - 4004.
  61. Linderholm B., Andersson J., Lindh B. et al. Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment // Eur. J. Cancer. 2004. V. 40. № 1. P.33 - 42.
  62. Linderholm B., Bergqvist J., Hellborg H. et al. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor // Med. Oncol. 2009. V. 26. № 4. P. 480 - 490.
  63. Linderholm B., Tavelin B., Grankvist K., Henriksson R. Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer - // Br. J. Cancer. 1999. V. 81. № 4. P. 727 - 732.
  64. Linderholm B.K., Gruvberger-Saal S., Ferno M. et al. Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer // Breast. 2008. V. 17. № 5. P. 484 - 491.
  65. Linderholm B.K., Hellborg H., Johansson U. et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer // Ann. Oncol. 2009. V. 20. № 10. P. 1639 - 1646.
  66. Linderholm B.K., Hellborg H., Johansson U. et al. Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer // Breast. Cancer Res. Treat. 2011. V. 125. № 2. P. 457 - 465.
  67. Locopo N., Fanelli M., Gasparini G. Clinical significance of angiogenic factors in breast cancer // Breast.
    Cancer Res. Treat. 1998. V. 52. № 1-3. P. 159 - 173.
  68. Lu W., Chen H., Yel F. et al. VEGF induces phosphorylation of STAT3 through binding VEGFR2 in ovarian carcinoma cells in vitro // Eur. J. Gynaecol. Oncol. 2006. V. 27. № 4. P. 363 - 369.
  69. Mahner S., Woelber L., Eulenburg C. et al. TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients // BMC Cancer. 2010. V. 10. P. 139.
  70. Molskness T.A., Stouffer R.L., Burry K.A. et al. Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and -2, and angiogenin during ovarian stimulation in non-human primates and women // Hum. Reprod. 2004. V. 19. № 4. P. 822 - 830.
  71. Obermair A., Kucera E., Mayerhofer K. et al. Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival // Int. J. Cancer. 1997. V. 74. № 4. P. 455 - 458.
  72. Okines A.F., Reynolds A.R., Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma // Oncologist. 2011. V. 16. № 6. P. 844 - 858.
  73. Relf M., LeJeune S., Scott P.A. et al.Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis // Cancer Res. 1997. V. 57. № 5. P. 963 - 969.
  74. Rogers P.A., Gargett C.E. Endometrial angiogenesis // Angiogenesis. 1998. V. 2. № 4. P. 287 - 294.
  75. Ryden L., Linderholm B., Nielsen N.H. et al. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer // Breast. Cancer Res. Treat. 2003. V. 82. № 3. P. 147 - 154.
  76. Salven P., Perhoniemi V., Tykka H. et al. Serum VEGF levels in women with a benign breast tumor or breast cancer // Breast. Cancer Res. Treat. 1999. V. 53. № 2. P. 161 - 166.
  77. Sandberg T., Ehinger A., Casslen B. Paracrine stimulation of capillary endothelial cell migration by endometrial tissue involves epidermal growth factor and is mediated via up-regulation of the urokinase plasminogen activator receptor // J. Clin. Endocrinol. Metab. 2001. V. 86. № 4. P. 1724 - 1730.
  78. Sato Y. Transcription factor ETS-1 as a molecular target for angiogenesis inhibition // Hum. Cell. 1998. V. 11. № 4. P. 207 - 214.
  79. Schips L., Dalpiaz O., Lipsky K. et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group // Eur. Urol. 2007. V. 51. № 1.
    P. 168 - 173; discussion 174.
  80. Scott P.A., Smith K., Poulsom R. et al. Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E // Br. J. Cancer. 1998. V. 77. № 12. P. 2120 - 2128.
  81. Shaarawy M., El-Sharkawy S.A. Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer // Acta. Oncol. 2001. V. 40. № 4. P. 513 - 518.
  82. Siddiqui G.K., Elmasry K., Wong Te Fong A.C. et al. Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer // Eur. J. Gynaecol. Oncol. 2010. V. 31. № 2. P. 156 - 159.
  83. Speirs V., Atkin S.L. Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours // Br. J. Cancer. 1999. V. 80. № 5 - 6. P. 898 - 903.
  84. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy // Biol. Pharm. Bull. 2011. V. 34. № 12. P. 1785 - 1788.
  85. Taponeco F., Curcio C., Giuntini A. et al. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer // J. Exp. Clin. Cancer Res. 2001. V. 20. № 2. P. 239 - 246.
  86. Toi M., Hoshina S., Takayanagi T., Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer // Jpn. J. Cancer Res. 1994.  V. 85. № 10. P. 1045 - 1049.
  87. Toi M., Inada K., Suzuki H., Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression // Breast Cancer Res. Treat. 1995. V. 36 (2). P. 193-204.
  88. Toi M., Kondo S., Suzuki H. et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer // Cancer. 1996. V. 77. № 6. P. 1101 - 1106.
  89. Vandenbunder B., Wernert N., Stehelin D. Does oncogene c-ets 1 participate in the regulation of tumor angiogenesis - // Bull. Cancer. 1993. V. 80. № 1. P. 38 - 49.
  90. Wang F.Q., So J., Reierstad S., Fishman D.A. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases // Int. J. Cancer. 2006. V. 118. № 4. P. 879 - 888.
  91. Wathen K.A., Unkila-Kallio L., Isaksson R. et al. Is serum-soluble vascular endothelial growth factor receptor-1 of importance in unexplained infertility? // Acta Obstet. Gynecol. Scand. 2008. V. 87. № 7. P.738 - 744.
  92. Xie B., Tam N.N., Tsao S.W., Wong Y.C. Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat // Br. J. Cancer. 1999. V. 81. № 8. P. 1335 - 1343.
  93. Yamamoto Y., Toi M., Kondo S. et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients // Clin. Cancer Res. 1996. V. 2. № 5. P. 821 - 826.
  94. Yen L., You X.L., Al Moustafa A.E. et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis // Oncogene. 2000. V. 19. № 31. P. 3460 - 3469.
  95. Yoshiji H., Gomez D.E., Shibuya M., Thorgeirsson U.P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer // Cancer Res. 1996. V. 56. № 9. P. 2013 - 2016.